TY - JOUR T1 - Correction: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial JF - Journal for ImmunoTherapy of Cancer JO - J Immunother Cancer DO - 10.1136/jitc-2020-000891corr1 VL - 9 IS - 5 SP - e000891corr1 A2 - , Y1 - 2021/05/01 UR - http://jitc.bmj.com/content/9/5/e000891corr1.abstract ER -